AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01678612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copper-alloy surfaced objects
Description: Room assigned to the Experimental arm will be furnished with copper-alloy surfaced objects,i.e. bed-rails, bed-rail levers, IV poles, nurse workstation, HCW clipboards, sink handles.
Study NCT03779815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Florbetaben
Description: * Drug: \[18F\]Florbetaben~* \[18F\]Florbetaben PET/CT Imaging for detecting amyloidosis in multiple myeloma~* Other name: Neuraceq~* Amount: 300 MBq ± 20% bolus, 10mL intravenously
Study NCT00516867 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UV radiation
Description: UV radiation with 99.5% UVA and 0.5%UVB
Study NCT00516867 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: UV radiation
Description: UVB 1.4 % and UVA 98.6
Study NCT00902707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex 1200mg
Description: Compared to Placebo
Study NCT00902707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Compare to active Mucinex
Study NCT02474407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diazepam nasal spray
Study NCT02474407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diazepam rectal gel
Study NCT05862311 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ELISA
Description: ELISA(enzyme-linked immunosorbent assay)
Study NCT04584957 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VAC therapy
Description: Prophylactic ciNPWT therapy (Prevena® KCI) entails placement of the device over a closed incision immediately post-operatively. Prevena® KCI may be left in place with no additional intervention for up to 7 days.
Study NCT01210586 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Part 2
Description: Comparing smoking symptomatology by HRT and nicotine patch status using a 2x2 randomized design.
Study NCT01210586 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Part 2
Description: Comparing smoking symptomatology by HRT and nicotine patch status using a 2x2 randomized design.
Study NCT01036932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulocyte Colony Stimulating Factor
Description: Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
Study NCT01036932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
Study NCT01145326 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 4% lidocaine gel application with sham microneedle device
Description: Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).
Study NCT01145326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microneedle-facilitated lidocaine application
Description: Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device
Study NCT03861624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing with standard SIGN nail
Description: Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the standard SIGN nail (SIGN Fracture Care International, Richland, WA). The number of interlocking screws is at the discretion of the treating surgeon, who also has the option to use an external fixator for damage control, and later conversion to IMN when clinically appropriate. The experimental group procedure is less common in the study setting, and thus, viewed as the experimental group.
Study NCT03861624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External Fixation with uniplanar Dispofix external fixator
Description: Patients meeting eligibility requirements are randomized to either study arm. Patients receive definitive fixation of AO/OTA-42 open tibia diaphyseal fractures using the uniplanar Dispofix external fixator with two Shanz screws placed proximally and two Schanz screws placed distally to fracture site with a single stainless steel bar.The active comparator group procedure is more common in the study setting, and thus, viewed as the comparator group.
Study NCT03408015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Lifitegrast ophthalmic solution, 5.0%. 1 drop instilled into each eye once in the morning and once before bed.
Study NCT02086669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic dilatation
Study NCT02086669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic myotomy
Study NCT01530321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: 5 minutes of high velocity, low amplitude thrust to cervical and upper thoracic spine.
Study NCT01923870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 25 mg
Study NCT04618653 — intervention group
Intervention type: OTHER
Intervention: assessment only
Description: Three assessment will include computerized assessments, interviews, and subset will provide daily reports of prescribed AA behaviors and practices
Study NCT01530321 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Light Massage
Description: 5 minutes of light pressure massage to the neck and upper back
Study NCT01530321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Light Massage
Description: 5 minutes of light pressure massage to the neck and upper back
Study NCT01188603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flibanserin 100 mg dose every evening
Description: all subjects receive flibanserin
Study NCT04750837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: debridement of the wound
Description: The edges and the floor of the wound were firstly debrided, and any callosities around the wound were removed. This was repeated if needed when callosities around the wound reappeared. By this technique, the chronic wound was transformed into an acute one
Study NCT04750837 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: debridement of the wound
Description: The edges and the floor of the wound were firstly debrided, and any callosities around the wound were removed. This was repeated if needed when callosities around the wound reappeared. By this technique, the chronic wound was transformed into an acute one
Study NCT04750837 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: platelet rich plasma
Description: Part of activated PRP was injected around the wound and under the base of the wound, while another portion of PRP was left over the floor of the wound and let to coagulate and form a gel.
Study NCT04750837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional dressing
Description: The wound was irrigated by normal saline, covered by vaseline gauze then sterile dressing. Repeated dressing every two days till 20 weeks, if the wound failed to heal at that time
Study NCT04750837 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: conventional dressing
Description: The wound was irrigated by normal saline, covered by vaseline gauze then sterile dressing. Repeated dressing every two days till 20 weeks, if the wound failed to heal at that time
Study NCT02572466 — intervention group
Intervention type: OTHER
Intervention: Hemodialysis
Description: ESRD group received long-term hemodialysis
Study NCT03323658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: Given topically
Study NCT03323658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00363454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triciribine Phosphate Monohydrate
Description: 8 Cycles @ 28 days. Level 1: 15 mg/m\^2; Level 2: 25 mg/m\^2; 35 mg/m\^2; 45 mg/m\^2.
Study NCT00881192 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IABP
Description: preoperative IABP placement
Study NCT04300569 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: No intervention will be administered.
Study NCT01005004 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HuCNS-SC cells
Description: intracerebral transplantation
Study NCT01132495 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Stenting plus OMT
Description: FFR guided PCI, plus OMT
Study NCT03947073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Three cartoon illustrated educational videos with information on gestational diabetes will be provided to the patient in addition to standard of care.
Study NCT01132495 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: OMT
Description: OMT alone
Study NCT01132495 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: FFR > 0.80; treatment according to local practice
Study NCT04152967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new-designed PTFE valved conduits
Description: In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
Study NCT04152967 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bovine jugular vein valved conduits
Description: In this prospective comparative research, all patients will be divided into two groups randomly with 100 patients in each group. One group will use the new-designed PTFE valved conduits and another one will implant the bovine jugular vein valved conduits.
Study NCT01860235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA
Description: % eutectic mixture of 25mg/g lidocaine and 25 mg/g of prilocaine
Study NCT01860235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injectable anesthesia
Description: Injectable anesthesia 2% lidocaine with epinephrine 1:100.000
Study NCT01860235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Benzocaine
Description: Topical anesthetic - 200mg/g of 2% benzocaine
Study NCT01876485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowering Patients in Chronic Care (EPIC)
Description: EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
Study NCT01876485 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
Study NCT02800330 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Esomeprazole 40mg concomitantly
Description: During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
Study NCT02800330 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Esomeprazole 40mg before
Description: During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
Study NCT02800330 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Regorafenib 160mg or 120mg
Description: Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)
Study NCT01074528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness based stress reduction program
Description: 8-week mindfulness training program
Study NCT03259126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCUT
Description: Two different home made curtains were attached to the angiographic table
Study NCT01887002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2952
Description: ONO-2952 Active tablets, every day for 2 weeks
Study NCT01887002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: ONO-2952 Matching Placebo every day for 2 weeks
Study NCT03012035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: positive treatment expectations
Description: Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
Study NCT03012035 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: neutral treatment expectations
Description: The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
Study NCT02805075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharide
Description: Given PO
Study NCT02805075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00916318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity-Children
Description: (A) internet based information and communication tool Sundabarn.se(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A, (C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A, (D) control group.
Study NCT00916318 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Obesity-Children
Description: (A) internet based information and communication tool Sundabarn.se(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A, (C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A, (D) control group.
Study NCT03230981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical imaging of the cornea in healthy subjects
Description: OCT vibrography and Brillouin microscopy
Study NCT02512315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (DOC)
Description: Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Docetaxel is given at a dose of 75mg/m2 on the first day of every cycle.
Study NCT02512315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP)
Description: Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Cisplatin is given at a dose of 75mg/m2 on the first day of every cycle.
Study NCT02512315 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiation (CCRT)
Description: The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).~The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly.
Study NCT02512315 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (CCRT)
Description: The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).~The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly.
Study NCT06584877 — intervention group
Intervention type: OTHER
Intervention: sample collection
Description: Surplus material from surgery. New or stored blood or saliva. Semen (from adult males).
Study NCT06584877 — intervention group
Intervention type: OTHER
Intervention: Seeking consent and assent
Description: Consent or assent from all participants to be included in the study. Consent from parent / guardian for inclusion of children in study (as primary participant or relative/sibling, as applicable).
Study NCT01203592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: 4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
Study NCT03146442 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Breakfast
Description: For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
Study NCT02816645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Study NCT02184312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine XR low dose
Study NCT02184312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine XR medium dose
Study NCT03146442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast
Description: For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
Study NCT03146442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
Study NCT02184312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine XR high dose
Study NCT02184312 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine (VIRAMUNE®)
Study NCT02637869 — intervention group
Intervention type: OTHER
Intervention: Alternative Payment Model
Description: Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
Study NCT02859025 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: anterior iliac crest graft
Description: Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.
Study NCT02859025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lateral ramus cortical bone+BFPSC+NBBM
Description: ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.
Study NCT02859025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anterior iliac crest graft+BFPSC+NBBM
Description: Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
Study NCT03398759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butorphanol
Description: IV injection during induction
Study NCT03398759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV injection during induction
Study NCT01973920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi Icp
Study NCT00738231 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
Study NCT00627913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Healon 5 injection
Description: Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
Study NCT00627913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthetic injection
Description: 3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
Study NCT01860235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
Study NCT00932191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard phacoemulsification
Description: Cataract nucleus removal using standard amounts of ultrasound energy
Study NCT00932191 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reduced ultrasound phacoemulsification
Description: Cataract nucleus removal using less ultrasound energy and more mechanical energy.